Free Trial
NASDAQ:OCS

Oculis Q2 2024 Earnings Report

Oculis logo
$17.84 -0.10 (-0.53%)
As of 02:23 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Oculis EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.43
Beat/Miss
Missed by -$0.13
One Year Ago EPS
N/A

Oculis Revenue Results

Actual Revenue
$0.27 million
Expected Revenue
$0.28 million
Beat/Miss
Missed by -$10.00 thousand
YoY Revenue Growth
N/A

Oculis Announcement Details

Quarter
Q2 2024
Time
N/A
Conference Call Date
Tuesday, August 27, 2024
Conference Call Time
4:00AM ET

Upcoming Earnings

Oculis' Q2 2025 earnings is scheduled for Tuesday, August 26, 2025

Earnings Documents

Oculis Earnings Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
See More Oculis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Oculis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oculis and other key companies, straight to your email.

About Oculis

Oculis (NASDAQ:OCS), a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

View Oculis Profile

More Earnings Resources from MarketBeat